142217-79-6

Basic information

• Product Name: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone
• Synonyms: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone;Entecavir interMediate 6;(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-Methoxyphenyl)diphenylMethyl]aMino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxyMethyl)cyclopentanone (interMediate step 5);(2R,3S,5S)-3-(Benzyloxy)-5-(6-(benzyloxy)-2-(((4-methoxyphenyl)diphenylmethyl)-amino)-9H-purin-9-;EntecavirinterMediate;(2R,3S,5S)-3-(Benzyloxy)-5-(6-(benzyloxy)-2-(((4-Methoxyphenyl)diphenylMethyl)aMino)-9H-purin-9-yl)-2-((benzyloxy)Methyl)cyclopentanone;(2R,3S,5S)-3-(Benzyloxy)-5-(6-(benzyloxy)-2-(((4-methoxyphenyl)diphenylmethyl)-amino)-9H-purin;Entecavir Impurity 2
• CAS NO: 142217-79-6
• Molecular Formula: C₅₂H₄₇N₅O₅
• Molecular Weight: 821.96
• Mol File: 142217-79-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.23
• Refractive Index: 1.645
• Storage Temp.: 2-8°C
• PKA: 2.75±0.30(Predicted)
• CAS DataBase Reference: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone(142217-79-6)
• EPA Substance Registry System: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone(142217-79-6)

Safety Data

• Hazardous Substances Data: 142217-79-6(Hazardous Substances Data)

Usage

General Description

The chemical "(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone" is a complex compound with multiple functional groups. It contains a cyclopentanone ring attached to a purine group, which is further connected to a diphenylmethylamino group and a benzyloxy group. Additionally, there are multiple benzyl groups present in the molecule. (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone is likely to have pharmaceutical applications due to the presence of the purine group, which is commonly found in drugs with central nervous system activity. Its complex structure suggests potential interactions with various biological targets, making it a promising candidate for further research and development.

InChI:InChI=1/C52H47N5O5/c1-59-43-29-27-42(28-30-43)52(40-23-13-5-14-24-40,41-25-15-6-16-26-41)56-51-54-49-47(50(55-51)62-34-39-21-11-4-12-22-39)53-36-57(49)45-31-46(61-33-38-19-9-3-10-20-38)44(48(45)58)35-60-32-37-17-7-2-8-18-37/h2-30,36,44-46H,31-35H2,1H3,(H,54,55,56)/t44-,45+,46+/m1/s1

Upstream product

• 4984-82-1 sodium cyclopentadienylide 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 142217-77-4 [1S-(1α,2β,3α,5β)]-5-(2-amino-6-benzyloxy-9H-purin-9-yl)-3-benzyloxy-2-(benzyloxy)methyl-cyclopentanol 
• 110567-21-0 (1S,2R)-2-(benzyloxymethyl)-1-hydroxy-3-cyclopentene 
• 117641-39-1 (2R,3S)-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexan-3-ol 
• 110567-22-1 (2R,3S)-benzyloxy-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexane 
• 39939-07-6 5-(benzyloxymethyl)cyclopentadiene 
• 3587-60-8 Benzyloxymethyl chloride 
• 142217-78-5 (1S,2S,3S,5S)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-benzyloxy-9H-purin-9-yl]-3-benzyloxy-2-[(benzyloxy)methyl]cyclopentanol 

Downstream Products

• 142217-80-9 6-(benzyloxy)-9-((1S,3R,4S)-4-(benzyloxy)-3-((benzyloxy)methyl)-2-methylidenecyclopentyl)-N-((4-methoxyphenyl)diphenylmethyl)-9H-purin-2-amine 
• 142217-81-0 2-amino-1,9-dihydro-9-[(1S,3R,4S)-2-methylene-4-(phenylmethoxy)-3-[(phenylmethoxy)methyl]cyclopentyl]-6H-purin-6-one 
• 142217-69-4 entecavir 

Relevant articles and documents

Improved entecavir intermediate synthesis process and improved entecavir synthesis process

The invention discloses an improved entecavir intermediate synthesis process and an improved entecavir synthesis process, and relates to the technical field of drug synthesis. The invention disclosesan improved entecavir intermediate synthesis process. In the synthesis process of an amino protection reaction product, amino protecting groups are added in batches; and the ratio of the reaction rawmaterials is optimized, so that the problems of long reaction time and relatively low amino protection reaction yield due to adoption of a one-time complete feeding mode in an existing synthesis modeare solved, the synthesis time of an amino protection reaction product is shortened to 50-70 minutes, and the obtained product is high in yield and purity. According to the improved entecavir synthesis process, in the amino protection reaction product synthesis process, reaction conditions are effectively optimized, and the purity of obtained entecavir reaches 99% or above.

BMS-200475, a novel carbocyclic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro

BMS-200475, a never carbocyclic analog of 2'-deoxyguanosine, is a potent inhibitor of hepatitis B virus in vitro (ED50 = 3 nM) with relatively low cytotoxicity (CC50 = 21-120 μM). A practical 10-step asymmetric synthesis was developed affording BMS-200475 in 18% overall chemical yield and > 99% optical purity. The enantiomer of BMS-200475 as well as the adenine, thymine, and iodouracil analogs are much less active.